Skip to main content
Home / Resources / Webinar / Webinar: What’s New in Physiologically-Based Pharmacokinetics & the Simcyp Simulator

Webinar: What’s New in Physiologically-Based Pharmacokinetics & the Simcyp Simulator

Live Webinar

Dr. Mark Lovern will provide an overview of recent drug development market and regulatory trends regarding adoption and acceptance of physiologically-based pharmacokinetic (PBPK) approaches, and how these challenges are being addressed by new features in v22 of the Simcyp Simulator.

Register

Thank you for registering!

Speakers
Mark Lovern
Mark R. Lovern, PhD
Senior Vice President, Commercial & Product Strategy, Simcyp Division
Dr. Mark Lovern has 20+ years of experience in using modeling and simulation to address drug development challenges. He enjoys teaching and mentorship and has a particular passion for helping quantitative pharmacologists be not just analysts but also effective communicators. Mark holds a Ph. D. in Biomathematics from North Carolina State and is the author of numerous publications. His favorite leisure activities include hosting dinner parties, traveling, reading, and enjoying films.
Masoud Jamei
Masoud Jamei, PhD
Senior Vice President, Simcyp Research & Development
Masoud leads teams of scientists and programmers on the design, development and implementation of various aspects of systems pharmacology including in vitro-in vivo extrapolation techniques, physiologically-based PK/PD models, and the application of top-down PopPK data analysis to PBPK models in healthy volunteer and patient populations.
Jean Dinh
Jean Dinh
Senior Research Scientist at Certara UK Limited, Simcyp Division
Jean obtained her PharmD and PhD in Medicinal Chemistry at the University of Washington in Seattle, WA. She completed a T-32 fellowship in Paediatric Clinical Pharmacology at Children’s Mercy Hospital in Kansas City, MO where she focused on children with attention deficit/hyperactivity disorder. Jean has experience working in the paediatrics, pregnancy/lactation, and populations teams in Simcyp.
Amaka Ezuruike
Udoamaka (Amaka) Ezuruike
Senior Research Scientist at Certara UK Limited, Simcyp Division
Amaka is a Senior Research Scientist in the Translational Science in DMPK team. She joined Simcyp in 2015 after completing her PhD in Pharmaceutical Sciences from the University College London for her research investigating pharmacokinetic herb-drug interactions amongst diabetic patients. She has been involved in the expansion of the capabilities of the Simcyp simulator, including the development and verification of population files and small molecule compound files, and the prediction of clinical drug-drug interactions.
Felix Stader
Felix Stader
Senior Research Scientist at Certara UK Limited, Simcyp Division
Felix studied biology and pharmaceutical science in Muenster (Germany) and did his PhD in Basel (Switzerland) about HIV drug pharmacokinetics and drug-drug interaction magnitudes in the elderly by using a Matlab model. At Certara UK, he worked extensively on the biologics models of the Simulator including subcutaneous absorption, antibody-drug conjugates and the possibility to simulate therapeutic protein disposition in paediatrics. Additionally, Felix has broad experience in developing population and compound files.